August 31, 2017 / 7:26 AM / in 4 months

BRIEF-Valneva H1 EBITDA rises to 7.6 million euros

Aug 31 (Reuters) - VALNEVA SE:

* ‍TOTAL REVENUES AND GRANTS OF EUR 55.4 MILLION IN H1 2017​

* ‍EBITDA INCREASED STRONGLY IN H1 2017 REACHING EUR 7.6 MILLION (VERSUS. EUR 4.7 MILLION IN H1 2016)​

* ‍POSITIVE OPERATING CASH FLOW AMOUNTED TO EUR 16.6 MILLION IN H1 2017 (VERSUS. EUR 3.9 MILLION IN H1 2016)​

* ‍REITERATES ITS INTENT TO LAUNCH PHASE I DEVELOPMENT OF ITS CHIKUNGUNYA VACCINE CANDIDATE LATE 2017 OR EARLY 2018​

* SEEKS TO PARTNER ITS CLOSTRIDIUM DIFFICILE VACCINE CANDIDATE AND HAS ONGOING DISCUSSIONS WITH INTERESTED PARTIES

* ‍COMPANY REAFFIRMS IT EXPECTS AN EBITDA OF EUR 5 TO EUR 10 MILLION IN 2017;​

* ‍H2 WILL HAVE LOWER EBITDA THAN H1 DUE TO SALES AND RESEARCH AND DEVELOPMENT COST PHASING​

* ‍CONFIRMS INTENTION TO GROW ITS REVENUES - BOTH ORGANICALLY AS WELL AS STRATEGICALLY - TO APPROXIMATELY EUR 250 MILLION IN MID-TERM​

* H1 LOSS FOR THE PERIOD EUR 4.4 MILLION VERSUS LOSS OF EUR 39.5 MILLION YEAR AGO

* ON LYME BORRELIOSIS VACCINE CANDIDATE: HAS NOW COMPLETED SUBJECT ENROLLMENT FOR ONGOING PHASE I STUDY;EXPECTS TO ANNOUNCE DATA IN THE Q1 2018

* CONFIRMS IT SEES OVERALL 2017 IFRS REVENUES AT EUR 105 MILLION TO EUR 115 MILLION, REFLECTING UP TO 17 PERCENT TOTAL REVENUE GROWTH YOY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below